These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 31440380)
1. Galectin-3 Mediates Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension. Li T; Zha L; Luo H; Li S; Zhao L; He J; Li X; Qi Q; Liu Y; Yu Z Aging Dis; 2019 Aug; 10(4):731-745. PubMed ID: 31440380 [TBL] [Abstract][Full Text] [Related]
2. Galectin-3 mediates pulmonary vascular remodeling in hypoxia-induced pulmonary arterial hypertension. Luo H; Liu B; Zhao L; He J; Li T; Zha L; Li X; Qi Q; Liu Y; Yu Z J Am Soc Hypertens; 2017 Oct; 11(10):673-683.e3. PubMed ID: 28826890 [TBL] [Abstract][Full Text] [Related]
3. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition. Shi R; Zhu D; Wei Z; Fu N; Wang C; Liu L; Zhang H; Liang Y; Xing J; Wang X; Wang Y Life Sci; 2018 Aug; 207():442-450. PubMed ID: 29969608 [TBL] [Abstract][Full Text] [Related]
5. Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4. He J; Li X; Luo H; Li T; Zhao L; Qi Q; Liu Y; Yu Z J Am Soc Hypertens; 2017 May; 11(5):275-289.e2. PubMed ID: 28431936 [TBL] [Abstract][Full Text] [Related]
6. Galectin-3 aggravates pulmonary arterial hypertension via immunomodulation in congenital heart disease. Shen Q; Chen W; Liu J; Liang Q Life Sci; 2019 Sep; 232():116546. PubMed ID: 31176777 [TBL] [Abstract][Full Text] [Related]
7. Galectin-3- Mediated Transdifferentiation of Pulmonary Artery Endothelial Cells Contributes to Hypoxic Pulmonary Vascular Remodeling. Zhang L; Li YM; Zeng XX; Wang XY; Chen SK; Gui LX; Lin MJ Cell Physiol Biochem; 2018; 51(2):763-777. PubMed ID: 30463073 [TBL] [Abstract][Full Text] [Related]
8. miR-181b-5p inhibits endothelial-mesenchymal transition in monocrotaline-induced pulmonary arterial hypertension by targeting endocan and TGFBR1. Zhao H; Wang Y; Zhang X; Guo Y; Wang X Toxicol Appl Pharmacol; 2020 Jan; 386():114827. PubMed ID: 31734320 [TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. de Mendonça L; Felix NS; Blanco NG; Da Silva JS; Ferreira TP; Abreu SC; Cruz FF; Rocha N; Silva PM; Martins V; Capelozzi VL; Zapata-Sudo G; Rocco PRM; Silva PL Stem Cell Res Ther; 2017 Oct; 8(1):220. PubMed ID: 28974252 [TBL] [Abstract][Full Text] [Related]
10. Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. Good RB; Gilbane AJ; Trinder SL; Denton CP; Coghlan G; Abraham DJ; Holmes AM Am J Pathol; 2015 Jul; 185(7):1850-8. PubMed ID: 25956031 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice. Li L; Wei C; Kim IK; Janssen-Heininger Y; Gupta S Hypertension; 2014 Jun; 63(6):1260-9. PubMed ID: 24614212 [TBL] [Abstract][Full Text] [Related]
12. The role of PDGF-B/TGF-β1/neprilysin network in regulating endothelial-to-mesenchymal transition in pulmonary artery remodeling. Song S; Zhang M; Yi Z; Zhang H; Shen T; Yu X; Zhang C; Zheng X; Yu L; Ma C; Liu Y; Zhu D Cell Signal; 2016 Oct; 28(10):1489-501. PubMed ID: 27373199 [TBL] [Abstract][Full Text] [Related]
13. Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline. Zhuang W; Lian G; Huang B; Du A; Xiao G; Gong J; Xu C; Wang H; Xie L Exp Biol Med (Maywood); 2018 Aug; 243(12):995-1003. PubMed ID: 30099957 [TBL] [Abstract][Full Text] [Related]
14. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling. Cheng G; Wang X; Li Y; He L Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784 [TBL] [Abstract][Full Text] [Related]
15. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension. Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861 [TBL] [Abstract][Full Text] [Related]
16. Dysregulation of miR-135a-5p promotes the development of rat pulmonary arterial hypertension in vivo and in vitro. Liu HM; Jia Y; Zhang YX; Yan J; Liao N; Li XH; Tang Y Acta Pharmacol Sin; 2019 Apr; 40(4):477-485. PubMed ID: 30038339 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of endocan attenuates monocrotaline-induced connective tissue disease related pulmonary arterial hypertension. Zhao H; Xue Y; Guo Y; Sun Y; Liu D; Wang X Int Immunopharmacol; 2017 Jan; 42():115-121. PubMed ID: 27912147 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats. Cheng Y; Yu M; Xu J; He M; Wang H; Kong H; Xie W BMC Pulm Med; 2018 Aug; 18(1):130. PubMed ID: 30086741 [TBL] [Abstract][Full Text] [Related]
19. Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension. Fulton DJR; Li X; Bordan Z; Wang Y; Mahboubi K; Rudic RD; Haigh S; Chen F; Barman SA Antioxid Redox Signal; 2019 Nov; 31(14):1053-1069. PubMed ID: 30767565 [No Abstract] [Full Text] [Related]
20. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension. Xi X; Liu S; Shi H; Yang M; Qi Y; Wang J; Du J Cardiovasc Toxicol; 2014 Dec; 14(4):368-78. PubMed ID: 24825325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]